VRTX — VERTEX PHARMACEUTICALS

Ownership history in Dempze Nancy E · 8 quarters on record

This page tracks every 13F SEC filing in which Dempze Nancy E reported a position in VERTEX PHARMACEUTICALS (VRTX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position

2.06% (2025 Q1)

Avg. % of fund

1.36%

First filed

2024 Q1

Last filed

2025 Q4

Quarters held

8

Quarter	Action	Shares	Change	Chg %	% of Fund	Mkt Value	Price (EOQ)
2025 Q4	REDUCED	7,058	-194	-2.7%	1.67%	$3.2M	$453.36
2025 Q3	ADDED	7,252	+72	+1.0%	1.56%	$2.8M	$391.64
2025 Q2	ADDED	7,180	+117	+1.7%	1.84%	$3.2M	$445.20
2025 Q1	ADDED	7,063	+986	+16.2%	2.06%	$3.4M	$484.82

% of Fund (quarterly) VRTX price (monthly, adj. close)

Other funds also holding VRTX

As of 2025 Q4 — sorted by position size

Provident Investment Management, Inc. 3Y 7Y 6.16% Bellevue Group AG 3Y 7Y 5.85% Andrew Hill Investment Advisors, Inc. 3Y 4.28% Iron Triangle Partners LP 3Y 3.99% Atle Fund Management AB 3Y 7Y 3.32% MCRAE CAPITAL MANAGEMENT INC 3Y 7Y 3.29% Sofinnova Investments, Inc. 3Y 7Y 3.22% SECTORAL ASSET MANAGEMENT INC 3Y 7Y 2.91% Birch Hill Investment Advisors LLC 3Y 7Y 2.89% NIA IMPACT ADVISORS, LLC 3Y 2.68%

← Back to Dempze Nancy E Holdings